SGHT - Sight Sciences, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 9.56 |
| Open | 9.67 |
| Bid | 7.41 x 900 |
| Ask | 7.62 x 800 |
| Day's Range | 7.32 - 9.67 |
| 52 Week Range | 5.35 - 15.30 |
| Volume | |
| Avg. Volume | 114,800 |
| Market Cap | 364.421M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.35 |
| Earnings Date | Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.60 |
Fair Value
Related Research
GlobeNewswireSight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology
Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 monthsSustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted through 24 monthsConfirmed safety and efficacy of OMNI Surgical System technology in both standalone and combination cataract proceduresLongest published multicenter clinical results of OMNI Surgical Syste
ZacksHow Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%
The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- GlobeNewswire
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surgery aloneMENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that enables procedures intended to improve patients' lives, today announced the results from a 12-month re
ZacksSight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
MENLO PARK, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights Generated first quarter revenue of $18.8 million, an increase of 26% compared to the
- GlobeNewswire
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Clinical data includes long-term trial results and robust real-world comparative data from IRIS® RegistryMENLO PARK, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, announced today that two of its proprietary glaucoma and dry eye technologies, the OMNI® Surgical System and the TearCare® System, will be featured in oral presentations and one
- GlobeNewswire
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Bank of America Securities 2023 Health Care Conference in Las Vegas, NV. Sight Sciences’ management is scheduled to present on Wednesday, May 10, 2023, at 3:40pm PT. Interested parties may access a live and archived webcast of the f
- GlobeNewswire
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the first quarter ended March 31, 2023, after the market close on Thursday, May 4, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. In
Simply Wall St.Why Investors Shouldn't Be Surprised By Sight Sciences, Inc.'s (NASDAQ:SGHT) P/S
You may think that with a price-to-sales (or "P/S") ratio of 5.9x Sight Sciences, Inc. ( NASDAQ:SGHT ) is a stock to...
- GlobeNewswire
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
The event will include presentations from leading glaucoma surgeons and remarks from the Sight Sciences executive management teamMENLO PARK, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will host a Surgical Glaucoma Investor Symposium in San Diego, CA on Friday, May 5, 2023 at 6:00
ZacksStrength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?
Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewswireSight Sciences Appoints Ali Bauerlein as Chief Financial Officer
Ali Bauerlein Ali Bauerlein has been appointed Sight Sciences’ Chief Financial Officer and Treasurer, effective April 3, 2023 MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April
- GlobeNewswire
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported that it defeated all four patent invalidity challenges filed by Alcon and Ivantis in the United States Patent and Trademark Office. Patent Infringement Litigation Over Hydrus® MicrostentOn September 16, 2021, the Company filed su
- Simply Wall St.
Owning 30% shares,institutional owners seem interested in Sight Sciences, Inc. (NASDAQ:SGHT),
Key Insights Significantly high institutional ownership implies Sight Sciences' stock price is sensitive to their...
Insider MonkeySight Sciences, Inc. (NASDAQ:SGHT) Q4 2022 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Hello, and welcome to Sight Sciences Fourth Quarter 2022 Earnings Results. At this time, all participants are in listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. I would now like to hand the conference over to Trip Taylor […]
ZacksSight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023. Recent Financial Highlights Generated 2022 total revenue of $71.3 million, an increase
GlobeNewswireSight Sciences Launches the Ergo-Series of the OMNI® Surgical System
The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures Ergo-Series of the OMNI® Surgical System by Sight Sciences, Inc. The Ergo-Series maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures MENLO PARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technolo
- GlobeNewswire
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Monday, March 13, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m
- GlobeNewswire
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
MENLO PARK, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York, NY. Sight Sciences’ management is scheduled to participate in a fireside chat on Wednesday, March 1, 2023, at 3:30pm ET. Interested parties may access a liv
Motley Fool3 Prime Healthcare Takeover Targets
Investors can win big when they invest in healthcare stocks that are likely takeover targets. CRISPR Therapeutics (NASDAQ: CRSP), BioMarin Pharmaceutical (NASDAQ: BMRN), and Sight Sciences (NASDAQ: SGHT) all stand out as potential healthcare stocks that are excellent takeover targets this year. CRISPR Therapeutics is one of the likeliest takeover targets among biotech stocks.
- GlobeNewswire
Sight Sciences Announces 1,000th TearCare® Customer Installation
Over 1,000 Professional Eye Care Practices Have integrated the TearCare® System to Treat Root Cause of Dry Eye Disease due to Meibomian Gland Dysfunction (MGD)MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced today the 1,000th installation of its TearCare® System. The TearCare® System i
- GlobeNewswire
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
Company Also Announces CFO TransitionMENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces several Company updates. Preliminary Revenue ResultsThe Company is announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022. Fourth quarter 202
- Simply Wall St.
Sight Sciences (NASDAQ:SGHT) adds US$55m to market cap in the past 7 days, though investors from a year ago are still down 17%
It is doubtless a positive to see that the Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has gained some 139% in the...
PR NewswireVerana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS Registry
Verana Health®—a digital health company elevating quality in real-world data (RWD)—and Sight Sciences, Inc. (NASDAQ: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced a research collaboration designed to provide insights that may lead to improved outcomes for patients with primary open-angle glaucoma (POAG).